Robert Thomas Dorr

Robert Thomas Dorr's AcademicInfluence.com Rankings

Robert Thomas Dorr

Medical

#3200

World Rank

#3655

Historical Rank

Pharmacology

#386

World Rank

#438

Historical Rank

medical Degrees

Robert Thomas Dorr

Philosophy

#9184

World Rank

#12704

Historical Rank

Ontology

#115

World Rank

#128

Historical Rank

Logic

#6173

World Rank

#7661

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Robert Thomas Dorr's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Robert Thomas Dorr Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert Thomas Dorr's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. (2003) (653)
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. (2001) (430)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. (2001) (413)
Cancer chemotherapy handbook (1980) (376)
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. (1995) (335)
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. (1993) (304)
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. (1994) (289)
Pharmacology and Toxicology of Cremophor EL Diluent (1994) (219)
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. (2005) (213)
Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. (1991) (205)
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. (1979) (194)
Antidotes to vesicant chemotherapy extravasations. (1990) (152)
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. (1998) (141)
Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. (1996) (136)
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. (2000) (127)
Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. (1992) (126)
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. (1996) (125)
Cytoprotective agents for anthracyclines. (1996) (125)
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. (1996) (125)
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. (1988) (107)
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II (2000) (104)
The state-of-the-art in chemoprevention of skin cancer. (2000) (97)
Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin (1999) (91)
Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. (2000) (90)
Interactions of mitomycin C with mammalian DNA detected by alkaline elution. (1985) (90)
Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization (2006) (89)
Induction of mitochondrial changes in myeloma cells by imexon. (2001) (84)
Human tumor models in the severe combined immune deficient (scid) mouse (1997) (80)
Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. (2000) (80)
Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. (1985) (80)
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. (2001) (79)
Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. (2002) (79)
A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. (1983) (76)
Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. (2001) (64)
Cimetidine decreases theophylline clearance. (1981) (63)
Disposition and metabolism of topically administered alpha-tocopherol acetate: a common ingredient of commercially available sunscreens and cosmetics. (1996) (63)
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. (1991) (61)
Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. (1982) (61)
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors (2015) (57)
Analogues of amonafide and azonafide with novel ring systems. (2000) (57)
New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. (1988) (57)
Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity. (1996) (56)
Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. (1987) (56)
Antitumor activity and murine pharmacokinetics of parenteral acronycine. (1989) (56)
Chemoprotectants for cancer chemotherapy. (1991) (55)
The clinical relevance of multidrug resistance. (1990) (55)
Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. (2004) (54)
The current status of laetrile. (1978) (54)
Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. (1993) (53)
Chemical basis for the biological activity of imexon and related cyanoaziridines. (2004) (52)
tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. (2001) (50)
Phase I trial of imexon in patients with advanced malignancy. (2007) (49)
A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors (2001) (49)
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent. (1993) (48)
Increased Eumelanin Expression and Tanning is Induced by a Superpotent Melanotropin [Nle4-d-Phe7]-α-MSH in Humans¶ (2000) (48)
Alpha‐globulins suppress human leukocyte tumor necrosis factor secretion (1989) (47)
UA62784, a novel inhibitor of centromere protein E kinesin-like protein (2009) (47)
Drug interactions with the taxanes: clinical implications. (2001) (46)
Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. (1996) (45)
Nordihydroguaiaretic Acid: A Review of Its Numerous and Varied Biological Activities (2004) (45)
Methotrexate: bioavailability and pharmacokinetics. (1985) (45)
Cutaneous ulceration due to contrast extravasation. Experimental assessment of injury and potential antidotes. (1991) (44)
Interferon-alpha in malignant and viral diseases. A review. (1993) (44)
Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. (1983) (42)
Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. (1987) (42)
Radioprotectants: pharmacology and clinical applications of amifostine. (1998) (41)
Case report: topical DMSO for mitomycin-C-induced skin ulceration. (1991) (40)
Skin Pigmentation and Pharmacokinetics of Melanotan‐I in Humans (1997) (39)
Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer (2009) (38)
Association of lysosomal activity with sensitivity and resistance to tumor necrosis factor in murine L929 cells. (1989) (38)
Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. (1989) (38)
Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. (2002) (37)
Experimental model of doxorubicin extravasation in the mouse. (1980) (37)
Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. (1985) (37)
Pharmacology of the Taxanes (1997) (36)
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship. (1995) (36)
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. (1996) (36)
Nabilone: a potent antiemetic cannabinol with minimal euphoria. (1977) (36)
Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. (1988) (36)
Skin ulceration potential of paclitaxel in a mouse skin model in vivo (1996) (35)
Melanotropic Peptides for Therapeutic and Cosmetic Tanning of the Skin (1993) (34)
Structure-activity relationships for mitomycin C and mitomycin A analogues. (1991) (34)
Design and synthesis of a novel DNA-DNA interstrand adenine-guanine cross-linking agent. (2001) (34)
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. (1992) (33)
Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases. (2002) (32)
Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice. (2000) (32)
Dosing considerations with amifostine: a review of the literature and clinical experience. (1999) (32)
Cytotoxic lignans from Larrea tridentata. (2005) (31)
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. (1993) (31)
Interferon-α in Malignant and Viral Diseases (1993) (31)
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer (2010) (31)
Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer (2004) (31)
Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. (1996) (30)
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo (2013) (30)
In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. (1988) (29)
Cimetidine enhancement of cyclophosphamide antitumour activity. (1982) (29)
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. (2014) (28)
Skin ulceration from extravasation of low-osmolality contrast medium: a complication of automation. (1992) (28)
Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. (2012) (27)
Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro. (1994) (27)
Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins. (2000) (26)
Discovery and development of novel melanogenic drugs. Melanotan-I and -II. (1998) (26)
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. (1981) (26)
Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells (2002) (25)
Interaction of allopurinol with 6-mercaptopurine and azathioprine. (1982) (25)
Glucose 6-phosphate dehydrogenase overexpression models glucose deprivation and sensitizes lymphoma cells to apoptosis. (2006) (24)
A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants (1996) (24)
1,4-disubstituted anthracene antitumor agents. (1997) (23)
The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response (2007) (22)
The effect of anticancer drug sequence in experimental combination chemotherapy. (1993) (22)
New antitumor agents containing the anthracene nucleus. (1987) (22)
Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones. (2000) (22)
Phase 1 Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer (2008) (22)
The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse (2004) (22)
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. (1996) (22)
Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines (2005) (21)
Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs. (1979) (21)
In vitro retinoid binding and release from a collagen sponge material in a simulated intravaginal environment. (1982) (21)
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. (2009) (21)
Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells (2012) (21)
Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. (1986) (20)
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer (2010) (20)
Correlates of imexon sensitivity in human multiple myeloma cell lines (2006) (19)
Transdermal delivery of a melanotropic peptide hormone analogue. (1988) (19)
alpha6 Integrin Cleavage: Sensitizing human prostate cancer to ionizing radiation (2007) (19)
Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. (2001) (19)
Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse (2004) (19)
Therapeutic Effect of Anthracene-Based Anticancer Agent Ethonafide in an Animal Model of Multiple Sclerosis1 (2007) (18)
Interaction of cimetidine but not ranitidine with cyclophosphamide in mice. (1986) (18)
Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells (2006) (18)
Effects of Chronic Intrathecal Infusion of a Opioid Agonist in Dogs (2003) (18)
Daily variation in non-protein sulfhydryl levels of human bone marrow. (1988) (17)
Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells (2004) (17)
Development and Testing of an Improved Parenteral Formulation of Phenytoin Using 2-Hydroxypropyl-β-cyclodextrin (2000) (17)
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines (2007) (16)
Organ culture of rat myocardial slices: An alternative in vitro tool in organ-specific toxicology (1992) (16)
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells. (1994) (16)
High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4‐day infusion (1989) (15)
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). (2008) (15)
Phase I-II Trial of Interferon-α2b by Continuous Subcutaneous Infusion over 28 Days (1988) (15)
Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics (1987) (15)
Preclinical pharmacokinetics and antitumor activity of imexon (2004) (15)
A phase 1‐2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma (2010) (14)
Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice (2006) (14)
Alkylation of DNA by C-10 of 2,7-diaminomitosene. (1990) (14)
In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[ de,h]isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides) (1997) (13)
Topical application of a melanotropic peptide induces systemic follicular melanogenesis. (1987) (13)
Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial. (1991) (13)
Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines. (1986) (13)
Allopurinol kinetics and bioavailability (2004) (13)
Topical absorption and inactivation of cytotoxic anticancer agents in vitro. (1992) (13)
Modulation of Experimental Doxorubicin Skin Toxicity by β-Adrenergic Compounds (1981) (12)
Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. (1982) (12)
Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study (1999) (12)
Novel antitumor 2-cyanoaziridine-1-carboxamides. (1999) (11)
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers (2013) (11)
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia. (1991) (11)
Phase II trial of vindesine in breast cancer, lymphoma and other tumors: future directions. (1980) (11)
Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro. (1989) (11)
Toxicologic studies of a superpotent α-melanotropin, [Nle4, D-Phe7]α-MSH (1988) (11)
Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. (1997) (11)
Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity. (1994) (11)
Incompatibilities with parenteral anticancer drugs (1979) (10)
Inapparent infiltrations associated with vindesine administration. (1979) (10)
Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. (1987) (10)
Coculture of rabbit liver and myocardial slices: Potentiation of the cardiotoxicity of allyl alcohol but not allylamine (1994) (10)
Effects of chronic intrathecal infusion of a partial differential opioid agonist in dogs. (2003) (10)
Pharmacologic Response of a Controlled-Release PLGA Formulation for the Alpha-Melanocyte Stimulating Hormone Analog, Melanotan-I (2000) (10)
Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells (2009) (9)
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase (2010) (9)
What is the appropriate management of tissue extravasation by antitumor agents (1985) (9)
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. (2012) (9)
Cimetidine enhances cisplatin toxicity in mice (1988) (9)
Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin (1998) (8)
Extravasation of vessicant antineoplastics: clinical and experimental findings. (1981) (8)
Mood alterations in patients treated with chlorambucil. (2003) (8)
Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer (2001) (8)
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line (2006) (8)
Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. (2011) (8)
Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan. (1987) (8)
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423 (2012) (8)
Absorption enhancement of melanotan-l: comparison of the caco-2 and rat in situ models (1995) (8)
Modulation of mitomycin C-induced multidrug resistance in vitro (2004) (8)
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues (1997) (8)
Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice. (1987) (8)
Administration of melanotropic peptides during gestation in the rodent. (1993) (7)
Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days. (1988) (7)
Development of a parenteral formulation for the anti-tumour agent acronycine (1988) (7)
Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone (2004) (7)
Bleomycin compatibility with selected intravenous medications. (1982) (7)
Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. (1988) (7)
Identification and characterization of in vitro metabolites of 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz [de,h]isoquinoline-1,3-dione (Azonafide). (1998) (7)
Coat color darkening in a dog in response to a potent melanotropic peptide. (1994) (7)
Pharmacokinetics and Safety of Green Tea Polyphenols after Multiple-Dose Administration of Epigallocatechin Gallate and Polyphenon E in Healthy Individuals 1 (2003) (6)
Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model1 (2016) (6)
Antidote studies of vinorelbine-induced skin ulceration in the mouse (1995) (6)
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents (2004) (6)
Allopurinol Absorption from Rectal Suppositories (1980) (6)
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation (2003) (6)
Controlled studies of a new microprocessor-based portable infusion pump. (1986) (6)
Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Worksho (2000) (5)
Vinca alkaloid ulceration: experimental mouse model and effects of local antidotes. Abstr. (1982) (5)
Nucleotide derivatives of 2,7-diaminomitosene. (1988) (5)
Synthesis and Antitumor Activity of Heterocycles Related to Carbendazim (2015) (5)
Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice (2005) (4)
Quantitation of ellipsoid tumor areas using a circumferential measuring device (1988) (4)
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. (1988) (4)
Synthesis of [14C]‐imexon (2005) (4)
H2-Antagonists and carmustine (1989) (4)
Cardiotoxicity of mitomycin A, mitomycin C, and sevenN7 analogs in vitro (2004) (4)
Intracellular localization of 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h]isoquino line-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity: an in vitro confocal microscopy study. (1999) (4)
Schedule-dependent toxicity of tumor necrosis factor in rodents. (1987) (4)
Mitomycin C toxicity and pharmacokinetics in mice given sulfur nucleophiles. (1988) (3)
Escalating costs for cancer chemotherapy. (1981) (3)
Chemistry and pharmacology of imexon and related cyanoaziridines. (2012) (3)
Bisantrene solubility and skin toxicity studies: Efficacy of sodium bicarbonate as a local ulceration antidote (2004) (3)
Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine 1 (2006) (3)
Biochemical effects and toxicity of mitoxantrone in cultured heart cells. (1991) (3)
Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells (2008) (3)
Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. (1998) (3)
Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids (1995) (2)
Interaction between cisplatin and mesna in mice (1989) (2)
Poor rectal absorption of trimethoprim/sulphamethoxazole in treating Pneumocystis carinii pneumonia. (1981) (2)
A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity (2008) (2)
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compounds. (1981) (1)
A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer (2008) (1)
Phase I trial of imexon (IMX) in patients (pts) with advanced solid tumors (2005) (1)
Imexon and gemcitabine are synergistic against human pancreatic cancer cells in vitro and in vivo (2005) (1)
Model of Multiple Sclerosis Anticancer Agent Ethonafide in an Animal Therapeutic Effect of Anthracene-Based and (2007) (1)
Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-beta-cyclodextrin. (2000) (1)
High incidence of local venous reactions to esorubicin (2004) (1)
Cold protection for intradermal (id) doxorubicin (dox) ulceration in the mouse. Abstr. (1983) (1)
Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma (2008) (1)
Phase I clinical trial of imexon: A mitochondrial thiol oxidant. (2004) (1)
Clinical pharmacology of taxanes as radiosensitizers and the thiol-based radioprotectant amifostine (1997) (0)
Commentary 4 (2012) (0)
CUTANEOUS ULCERATION DUE TO CONTRAST EXTRAVASATION: ASSESSMENT OF INJURY AND POTENTIAL ANTIDOTES (1989) (0)
Procede de stimulation de la production de melanine et induction du bronzage (2003) (0)
Erratum: 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure- activity relationships (Journal of Medicinal Chemistry (1997) 40 (2660)) (1997) (0)
Characterization of a membrane-active anti-tumor agent, UA8967 (2013) (0)
TheAntitumorAgent Imexon Activates Antioxidant Gene Expression : Evidence for an Oxidative Stress Response (2007) (0)
A Melanotropic Peptide Induces Pigmentation (Tanning) of Human Skin (1992) (0)
579 Selective cardioprotection of rat heart myocytes exposed to DNA intercalating agents using amifostine (Ami) and its dephosphorylated metabolite, WR-1065 (1995) (0)
Book Review: Pharmacologic Principles of Cancer Treatment (1983) (0)
Procede de stimulation de melanocytes par l'application topique d'analogues d'alpha-msh, et compositions utilisees (1987) (0)
[A familial translocation t(13;17) (q14;q22) diagnosed following the birth of an infant with trisomy 21]. (1975) (0)
Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study (2013) (0)
Author reply (1997) (0)
IDENTIFICATION AND CHARACTERIZATION OF IN VITRO METABOLITES OF 2-[ 2 *-( DIMETHYLAMINO ) ETHYL ]-1 , 2-DIHYDRO-3 H-DIBENZ (1998) (0)
Method and pharmaceutical composition for the stimulation of the melamine production in a mammal (1987) (0)
Characterization of a mitomycin C (MMC) resistant L-1210 cell line (1985) (0)
Abstract 671: Tumor delay and mechanism of action studies of a novel cyanoaziridine derivative, AMP423 (2011) (0)
Cytotoxic Agent Chemoprotection with Thiols (1995) (0)
MITOMYCIN C METABOLISM AND INTERACTION WITH SULFUR NUCLEOPHILES IN BONE MARROW, DNA, AND CLONOGENIC TUMOR CELLS (ANTICANCER, ANTIBIOTIC). (1984) (0)
Agents anticancereux a base de 1,2-dihydro-3h-dibenzisoquinoline-1,3-diones (1991) (0)
Pulsed Electromagnetic Fields do Not Reduce Vesicant Skin Ulcers in Mice (1986) (0)
Injection needle with an automatically-applying shell. (1989) (0)
432 POSTER Phase I study of Amplimexon™ (imexon, inj.) in patients with advanced solid tumors and lymphomas: final report (2006) (0)
Mitomycin, ifosfamide, and mesna in the treatment of lung cancer. (1990) (0)
DNA Damage and Cellular Stress Responses Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells (2012) (0)
Evaluation of a portable infusion pump in ambulatory patients receiving continuous intravenous chemotherapy (1978) (0)
The Management of Cancer in the Pregnant Patient (1991) (0)
Recent advances in the management of lung and breast cancer: Introduction (1990) (0)
Increased Eumelanin Expression and Tanning is Induced by a Superpotent Melanotropin [Nle4‐d‐Phe7]‐α‐MSH in Humans ¶ (2000) (0)
Dosing error in protocol book. (1994) (0)
2-(2′-(Dimethylamino)ethyl)-1,2-dihydro-3H-dibenz(de,h)isoquinoline-1, 3-diones with Substituents at Positions 4, 8, 9, 10, and 11. Synthesis, Antitumor Activity, and Quantitative Structure-Activity Relationships. (2010) (0)
Safety of Autotranspiants with High-Dose Meiphalan in Renal Failure: A Pharmacokinetic and Toxicity Study1 (2005) (0)
Abstract B42: Adaptive drug resistance is associated with phenotypic reprogramming and hypersensitivity to HDAC inhibitors (2015) (0)
Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma (2007) (0)
Correction to Cancer Therapy Protocols. (1994) (0)
Abstract 797: Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with characteristics of EMT (2012) (0)
Conditioning Regimens Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation (2003) (0)
Redox Proteins GSTs A1, M1, O1, O2, P1; Prx-3, and Trx-1 Association with In Vitro Imexon Sensitivity in Multiple Myeloma Cell Lines. (2006) (0)
Aziridinyl Quinone Antitumor Agents Based on Indoles and Cyclopent[b]indoles: Structure—Activity Relationships for Cytotoxicity and Antitumor Activity. (2002) (0)
VerapumiI Reversal of Doxorubicin Resistance in Multidrug-resistant Human Myeloma Cells and Association with Drug Accumulation and DNA Damage1 (2006) (0)
Bortezomib-mediated stabilization of topoisomerase II potentiates the cytotoxic activity of ethonafide (AMP-53, 6-ethoxyazonafide) in myeloma cells. (2007) (0)
Phase I/II trial of Amplimexon (imexon, inj.) plus dacarbazine in patients with stage III or IV malignant melanoma (2006) (0)
ERECTOGENIC PROPERTIES OF MELANOTAN II IN MEN WITH ORGANIC ERECTILE DYSFUNCTION (1999) (0)
SYNTHETIC MELANOTROPIC PEPTIDE INITIATES ERECTIONS IN MEN PLACEBO CONTROLLED CROSSOVER STUDY WITH PSYCHOGENIC ERECTILE DYSFUNCTION: DOUBLE-BLIND, (1998) (0)
A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies (2000) (0)
Guidelines for Intravenous Drugs (1976) (0)
Antitumor Activity and Murine Pharmacokinetics (2006) (0)
Method of stimulating melanocytes by locally install of alpha-MSH analogue, and compositions. (1987) (0)
JPET #156406 1 Characterization of Novel Diaryloxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert Thomas Dorr?

Robert Thomas Dorr is affiliated with the following schools:

Robert Thomas Dorr's Academic­Influence.com Rankings

Robert Thomas Dorr's Degrees

Why Is Robert Thomas Dorr Influential?

Robert Thomas Dorr's Published Works

Published Works

What Schools Are Affiliated With Robert Thomas Dorr?

Robert Thomas Dorr's AcademicInfluence.com Rankings